{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T07:47:45Z","timestamp":1785916065108,"version":"3.56.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Amgen Korea"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40119-025-00430-8","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T03:38:17Z","timestamp":1759894697000},"page":"619-633","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Safety and Effectiveness of Evolocumab in Korean Patients with Atherosclerotic Cardiovascular Disease or Familial Hypercholesterolemia: A Post-Marketing Surveillance Study"],"prefix":"10.1007","volume":"14","author":[{"given":"Donggyu","family":"Moon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3895-1915","authenticated-orcid":false,"given":"Seung-Ho","family":"Hur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5845-2232","authenticated-orcid":false,"given":"Sang-Rok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2424-810X","authenticated-orcid":false,"given":"Myung Ho","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0377-6352","authenticated-orcid":false,"given":"Kyung Hoon","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6857-8632","authenticated-orcid":false,"given":"Osung","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4235-1040","authenticated-orcid":false,"given":"JinSeon","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5425-1102","authenticated-orcid":false,"given":"Ki Dong","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Evolocumab Post-Marketing Surveillance Research Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"430_CR1","unstructured":"Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) results. Seattle: Institute for Health Metrics and Evaluation (IHME); 2020. Available at: http:\/\/ghdx.healthdata.org\/gbdresults-tool. Accessed November 18, 2024."},{"issue":"32","key":"430_CR2","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459\u201372.","journal-title":"Eur Heart J"},{"issue":"12","key":"430_CR3","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jama.2016.13985","volume":"316","author":"MG Silverman","year":"2016","unstructured":"Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316(12):1289\u201397.","journal-title":"JAMA"},{"issue":"5","key":"430_CR4","doi-asserted-by":"publisher","first-page":"190","DOI":"10.31083\/j.rcm2505190","volume":"25","author":"LA Leiter","year":"2024","unstructured":"Leiter LA, Hegele RA, Brown V, Bergeron J, Mackinnon ES, Mancini GBJ. Review of evolocumab for the reduction of LDL cholesterol and secondary prevention of atherosclerotic cardiovascular disease. Rev Cardiovasc Med. 2024;25(5):190.","journal-title":"Rev Cardiovasc Med"},{"issue":"17","key":"430_CR5","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1136\/heartjnl-2020-318760","volume":"107","author":"C Packard","year":"2021","unstructured":"Packard C, Chapman MJ, Sibartie M, Laufs U, Masana L. Intensive low-density lipoprotein cholesterol lowering in cardiovascular disease prevention: opportunities and challenges. Heart. 2021;107(17):1369\u201375.","journal-title":"Heart"},{"issue":"16","key":"430_CR6","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1161\/CIRCULATIONAHA.122.063399","volume":"147","author":"P Gaba","year":"2023","unstructured":"Gaba P, O\u2019Donoghue ML, Park JG, et al. Association between achieved low-density lipoprotein cholesterol levels and long-term cardiovascular and safety outcomes: an analysis of FOURIER-OLE. Circulation. 2023;147(16):1192\u2013203.","journal-title":"Circulation"},{"issue":"15","key":"430_CR7","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","volume":"146","author":"ML O'Donoghue","year":"2022","unstructured":"O\u2019Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation. 2022;146(15):1109\u201319.","journal-title":"Circulation"},{"key":"430_CR8","doi-asserted-by":"publisher","first-page":"7362551","DOI":"10.1155\/2023\/7362551","volume":"2023","author":"HD Choi","year":"2023","unstructured":"Choi HD, Kim JH. An updated meta-analysis for safety evaluation of alirocumab and evolocumab as PCSK9 inhibitors. Cardiovasc Ther. 2023;2023:7362551.","journal-title":"Cardiovasc Ther"},{"issue":"1","key":"430_CR9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s10557-021-07255-2","volume":"37","author":"O Kwon","year":"2023","unstructured":"Kwon O, Na W, Hur J, et al. Cardiovascular event rates in statin-treated Korean patients with cardiovascular disease: estimates from a real-world population using electronic medical record data. Cardiovasc Drugs Ther. 2023;37(1):129\u201340.","journal-title":"Cardiovasc Drugs Ther"},{"key":"430_CR10","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","volume":"372","author":"MS Sabatine","year":"2015","unstructured":"Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500\u20139.","journal-title":"N Engl J Med"},{"issue":"18","key":"430_CR11","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"20","key":"430_CR12","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","volume":"74","author":"KC Koskinas","year":"2019","unstructured":"Koskinas KC, Windecker S, Pedrazzini G, et al. Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS). J Am Coll Cardiol. 2019;74(20):2452\u201362.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"430_CR13","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1161\/CIRCULATIONAHA.120.046320","volume":"142","author":"TM Leucker","year":"2020","unstructured":"Leucker TM, Blaha MJ, Jones SR, et al. Effect of evolocumab on atherogenic lipoproteins during the peri- and early postinfarction period: a placebo-controlled, randomized trial. Circulation. 2020;142(4):419\u201321.","journal-title":"Circulation"},{"issue":"24","key":"430_CR14","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","volume":"73","author":"S Grundy","year":"2019","unstructured":"Grundy S, Stone N, Bailey A, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol. 2019;73(24):3168\u2013209.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"430_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk [published correction appears in Eur Heart J. 2020 Nov 21;41(44):4255]. Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"key":"430_CR16","first-page":"191","volume":"12","author":"CE Kosmas","year":"2020","unstructured":"Kosmas CE, Skavdis A, Sourlas A, et al. Safety and tolerability of PCSK9 inhibitors: current insights. Clin Pharmacol. 2020;12:191\u2013202.","journal-title":"Clin Pharmacol"},{"key":"430_CR17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.athplu.2021.08.009","volume":"45","author":"M Blanco-Ruiz","year":"2021","unstructured":"Blanco-Ruiz M, Amaya-Pascasio L, de Torres Chac\u00f3n R, et al. Effectiveness and safety of PCSK9 inhibitors in real-world clinical practice. An observational multicentre study. The IRIS-PCSK9I study. Atheroscler Plus. 2021;45:32\u20138.","journal-title":"Atheroscler Plus"},{"key":"430_CR18","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s11883-022-01008-8","volume":"24","author":"T Altschmiedov\u00e1","year":"2022","unstructured":"Altschmiedov\u00e1 T, Todorovov\u00e1 V, \u0160nejdrlov\u00e1 M, et al. PCSK9 inhibitors in real-world practice: analysis of data from 314 patients and 2 years of experience in a center of preventive cardiology. Curr Atheroscler Rep. 2022;24:357\u201363.","journal-title":"Curr Atheroscler Rep"},{"issue":"5","key":"430_CR19","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/clc.23600","volume":"44","author":"NR Desai","year":"2021","unstructured":"Desai NR, Wade RL, Xiang P, et al. Low-density lipoprotein cholesterol lowering in real-world patients treated with evolocumab. Clin Cardiol. 2021;44(5):715\u201322.","journal-title":"Clin Cardiol"},{"issue":"4","key":"430_CR20","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s40119-023-00334-5","volume":"12","author":"M Gupta","year":"2023","unstructured":"Gupta M, Wani RJ, Al Faraidy K, et al. Real-world insights into evolocumab use in patients with hyperlipidemia across five countries: analysis from the ZERBINI study. Cardiol Ther. 2023;12(4):703\u201322.","journal-title":"Cardiol Ther"},{"issue":"5","key":"430_CR21","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3904\/kjim.2024.080","volume":"39","author":"Y Kim","year":"2024","unstructured":"Kim Y, Roh JW, Lee OH, et al. Efficacy of single-dose evolocumab injection in early-phase acute myocardial infarction: a retrospective single-center study. Korean J Intern Med. 2024;39(5):793\u2013800.","journal-title":"Korean J Intern Med"},{"issue":"4","key":"430_CR22","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s40119-024-00389-y","volume":"13","author":"MC Kim","year":"2024","unstructured":"Kim MC, Lee SH, Ahn JH, et al. Real-world application of Evolocumab among patients with hyperlipidemia in Korea: a multicenter prospective study. Cardiol Ther. 2024;13(4):695\u2013706.","journal-title":"Cardiol Ther"},{"issue":"21","key":"430_CR23","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.035809","volume":"13","author":"K Yokote","year":"2024","unstructured":"Yokote K, Ako J, Kitagawa K, et al. Safety and effectiveness of low-density lipoprotein cholesterol-lowering therapy with evolocumab for familial hypercholesterolemia\/hypercholesterolemia in japan: a real-world, postmarketing, single-arm study. J Am Heart Assoc. 2024;13(21): e035809.","journal-title":"J Am Heart Assoc"},{"issue":"17","key":"430_CR24","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1016\/j.jacc.2019.08.1024","volume":"74","author":"MJ Koren","year":"2019","unstructured":"Koren MJ, Sabatine MS, Giugliano RP, et al. Long-term efficacy and safety of evolocumab in patients with hypercholesterolemia. J Am Coll Cardiol. 2019;74(17):2132\u201346.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"430_CR25","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1253\/circj.CJ-20-1051","volume":"85","author":"AC Keech","year":"2021","unstructured":"Keech AC, Oyama K, Sever PS, et al. Efficacy and safety of long-term evolocumab use among Asian subjects\u2014a subgroup analysis of the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial. Circ J. 2021;85(11):2063\u201370.","journal-title":"Circ J"},{"issue":"12","key":"430_CR26","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","volume":"5","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Leiter LA, Wiviott SD, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(12):941\u201350.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"430_CR27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1001\/jamacardio.2020.3151","volume":"6","author":"P Deedwania","year":"2021","unstructured":"Deedwania P, Murphy SA, Scheen A, et al. Efficacy and safety of PCSK9 inhibition with evolocumab in reducing cardiovascular events in patients with metabolic syndrome receiving statin therapy: secondary analysis from the FOURIER randomized clinical trial. JAMA Cardiol. 2021;6(2):139\u201347.","journal-title":"JAMA Cardiol"},{"issue":"7","key":"430_CR28","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1056\/NEJMoa1701131","volume":"377","author":"RP Giugliano","year":"2017","unstructured":"Giugliano RP, Mach F, Zavitz K, et al. Cognitive function in a randomized trial of evolocumab. N Engl J Med. 2017;377(7):633\u201343.","journal-title":"N Engl J Med"},{"issue":"5","key":"430_CR29","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1161\/STROKEAHA.119.027759","volume":"51","author":"RP Giugliano","year":"2020","unstructured":"Giugliano RP, Pedersen TR, Saver JL, et al. Stroke prevention with the PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitor evolocumab added to statin in high-risk patients with stable atherosclerosis. Stroke. 2020;51(5):1546\u201354.","journal-title":"Stroke"},{"issue":"4","key":"430_CR30","first-page":"447","volume":"8","author":"KK Ray","year":"2022","unstructured":"Ray KK, Dhalwani N, Sibartie M, et al. Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study. Eur Heart J. 2022;8(4):447\u201360.","journal-title":"Eur Heart J"},{"key":"430_CR31","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.atherosclerosis.2023.01.002","volume":"366","author":"KK Ray","year":"2023","unstructured":"Ray KK, Bruckert E, Peronne-Filardi P, et al. Long-term persistence with evolocumab treatment and sustained reductions in LDL-cholesterol levels over 30 months: final results from the European observational HEYMANS study. Atherosclerosis. 2023;366:14\u201321.","journal-title":"Atherosclerosis"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-025-00430-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-025-00430-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-025-00430-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T16:14:29Z","timestamp":1764951269000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-025-00430-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["430"],"URL":"https:\/\/doi.org\/10.1007\/s40119-025-00430-8","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JinSeon Jeong is an employee of Amgen. Kyung Hoon Cho has received an institutional research grant from Amgen; speaker\/consulting honoraria from Amgen, Sanofi-Aventis, Viatris, Jeil Pharm, Aju Pharm, and JW Pharm. Donggyu Moon, Seung-Ho Hur, Sang-Rok Lee, Myung Ho Jeong, Osung Kwon, and Ki Dong Yoo declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was approved by the Institutional Review Board at each study site (representatively, no. VC21OSDE0224 of the St Vincent's Hospital Ethics Review Committee), and the study was conducted in accordance with the Declaration of Helsinki. For a complete list of the ethics committees of participating hospitals, see the electronic supplementary file, Supplementary Material. All enrolled patients provided informed consent to participate in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}